Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Just 1 in 4 Residential Programs Offer Buprenorphine for Adolescents
06/14/2023
Only 1 in 4 residential addiction treatment facilities caring for adolescents in the US offers buprenorphine, with just 1 in 8 offering buprenorphine for ongoing treatment, according to an Oregon Health & Science University study released on...
Only 1 in 4 residential addiction treatment facilities caring for adolescents in the US offers buprenorphine, with just 1 in 8 offering buprenorphine for ongoing treatment, according to an Oregon Health & Science University study released on...
Only 1 in 4 residential...
06/14/2023
Addiction Professional
smoking
News
Varenicline Improves Smoking Abstinence in Individuals With MDD
06/13/2023
In smokers with MDD, varenicline improved 27-week smoking cessation compared with placebo, according to recent study results.
In smokers with MDD, varenicline improved 27-week smoking cessation compared with placebo, according to recent study results.
In smokers with MDD, varenicline...
06/13/2023
Psych Congress Network
News
FDA Clears New Buprenorphine Option to Treat OUD
05/24/2023
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new...
05/24/2023
Addiction Professional
News
New Opioid Overdose Reversal Nasal Spray Receives FDA Approval
05/23/2023
The US Food and Drug Administration has approved Opvee, a new opioid overdose reversal nasal spray for patients at least 12 years of age. The medication was developed by a pharmaceutical company within the Indivior portfolio.
The US Food and Drug Administration has approved Opvee, a new opioid overdose reversal nasal spray for patients at least 12 years of age. The medication was developed by a pharmaceutical company within the Indivior portfolio.
The US Food and Drug...
05/23/2023
Addiction Professional
News
Black, Hispanic Patients Receive MOUD After Opioid-Related Events Less Frequently Than White Patients
05/16/2023
A study by researchers at Harvard University and Dartmouth College shows a discrepancy in the rates in which various populations receive medications for opioid use disorder despite making a similar number of visits to healthcare providers.
A study by researchers at Harvard University and Dartmouth College shows a discrepancy in the rates in which various populations receive medications for opioid use disorder despite making a similar number of visits to healthcare providers.
A study by researchers at...
05/16/2023
Addiction Professional
News
More Dangerous Substances Require More Proactive Efforts, Officials Say
04/12/2023
With deaths involving fentanyl and xylazine rising, NIDA Director Nora Volkow, MD, NIH Director Lawrence Tabak, DDS, PhD, and NIAAA Director George Koob, PhD, presented research updates and developments in substance use disorder treatment to...
With deaths involving fentanyl and xylazine rising, NIDA Director Nora Volkow, MD, NIH Director Lawrence Tabak, DDS, PhD, and NIAAA Director George Koob, PhD, presented research updates and developments in substance use disorder treatment to...
With deaths involving fentanyl...
04/12/2023
Addiction Professional
News
Medication-Assisted and Abstinence-Based Treatment Approaches Can Share Common Ground
04/11/2023
At the Rx Summit, presenters Robert DuPont, MD, Cara Poland, MD, MEd, FACP, DFASAM, and Gresha Eberly, CPRC, explained the philosophical conflicts between different approaches to addiction treatment and what providers of each can learn from...
At the Rx Summit, presenters Robert DuPont, MD, Cara Poland, MD, MEd, FACP, DFASAM, and Gresha Eberly, CPRC, explained the philosophical conflicts between different approaches to addiction treatment and what providers of each can learn from...
At the Rx Summit, presenters...
04/11/2023
Addiction Professional
News
Buprenorphine Initiation in ER Found Safe and Effective for Patients Using Fentanyl
03/31/2023
Findings from the National Institutes of Health-supported study indicate OUD treatment with buprenorphine can be safely started in an emergency department without triggering withdrawal, even among individuals who use stronger opioids.
Findings from the National Institutes of Health-supported study indicate OUD treatment with buprenorphine can be safely started in an emergency department without triggering withdrawal, even among individuals who use stronger opioids.
Findings from the National...
03/31/2023
Addiction Professional
News
FDA Approves Narcan for Over-The-Counter Use
03/29/2023
The US Food and Drug Administration (FDA) on Wednesday announced that it has approved Narcan, 4 milligram naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. Narcan becomes the first naloxone product approved for use...
The US Food and Drug Administration (FDA) on Wednesday announced that it has approved Narcan, 4 milligram naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. Narcan becomes the first naloxone product approved for use...
The US Food and Drug...
03/29/2023
Addiction Professional
News
Study Highlights Prevalence of Buprenorphine “Spiking” in Urine Screenings for OUD Patients
03/28/2023
More than 7% of urine samples collected in a cross-sectional study showed evidence of buprenorphine “spiking”—the intentional addition of buprenorphine tablet or residue directly into urine to mimic prescription adherence.
More than 7% of urine samples collected in a cross-sectional study showed evidence of buprenorphine “spiking”—the intentional addition of buprenorphine tablet or residue directly into urine to mimic prescription adherence.
More than 7% of urine samples...
03/28/2023
Addiction Professional

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement